{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"title":"Specificity of 68Ga-DOTATOC"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"title":"Specificity of Octreoscan"},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.82"}]}],"title":"Specificity of Conventional Imaging (CI)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"description":"Compare specificity of 68Ga-DOTATOC PET/CT with Octreoscan + high-resolution, contrast-enhanced CT for diagnosis and staging in neuroendocrine tumors and other somatostatin receptor positive tumors","groups":[{"description":"Patients receive gallium Ga 68-edotreotide IV and undergo PET/CT scan. Within 120 days, patients undergo standard indium In 111 pentetreotide contrast-enhanced CT or MRI scan. Patients may undergo a second gallium Ga 68-edotreotide PET/CT scan within 3-6 months if the lesions of the first scan cannot be confirmed.\n\ngallium Ga 68-edotreotide: Given IV\n\npositron emission tomography/computed tomography: Undergo gallium Ga 68-edotreotide PET/CT scan\n\nindium In 111 pentetreotide: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan\n\ncomputed tomography: Undergo indium In 111 pentetreotide contrast-enhanced CT scan\n\ncontrast-enhanced magnetic resonance imaging: Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan","id":"OG000","title":"Diagnostic (Gallium Ga 68-edotreotide PET/CT)"}],"paramType":"NUMBER","populationDescription":"Patients with neuroendocrine tumor or other somatostatin receptor positive tumor","reportingStatus":"POSTED","timeFrame":"6 months","title":"Compare Specificity of 68Ga-DOTATOC PET/CT With Octreoscan","type":"PRIMARY","unitOfMeasure":"percentage of specificity"}